Business Context and Reporting Period
This Form 8-K Current Report was filed by Revelation Biosciences, Inc. on January 10, 2023. The filing addresses a mandatory corporate action regarding the separation of the company's trading units on the Nasdaq Capital Market.
Key Financial Metrics
This filing is a current report regarding a corporate event and does not provide financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. No financial data is present in this document.
Material Changes
The primary material event reported is the mandatory separation of the company's units (ticker: REVBU). Effective January 13, 2023:
- Units will cease trading on the Nasdaq Capital Market.
- Each unit, consisting of one share of common stock and one redeemable warrant, will be automatically separated.
- Unit holders will receive the underlying common stock (ticker: REVB) and warrants (ticker: REVBW) separately.
- No action is required by unit holders to effect this separation.
Guidance, Outlook, and Risks
The filing contains no management guidance, financial outlook, or discussion of risks and contingencies beyond the operational details of the unit separation. The document references a press release (Exhibit 99.1) for further details but does not include the text of that release.
Investor Verification Checklist
- Verify the trading status of REVBU units on or after January 13, 2023.
- Confirm the separate listing and ticker symbols for the common stock (REVB) and warrants (REVBW) on the Nasdaq Capital Market.
- Review the attached press release (Exhibit 99.1) for any additional details regarding the separation process not included in the 8-K summary.
- Note that the warrant exercise price is $11.50 per share.